linjc16/ctgov huggingface dataset:
Blood Types in Children With COVID-19

Study Overview
=================
Brief Summary
-----------------
It is speculated that in adult patients with COVID-19 blood type A is associated with the worst outcome, while blood type O is associated with mild symptoms.To our knowledge, there has been no such a study investigated ABO and Rhesus (Rh) blood group types in children with COVID-19 infection yet. Therefore, the study aimed to examine if such a correlation exists in children infected with COVID-19.

Official Title
-----------------
ABO-Rh Blood Types and COVID-19 Infection in Children: Is There a Link?

Conditions
-----------------
COVID-19 Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study period consisted between March 2020 and December 2020 Children with a documented positive COVID-19 nasal smear real-time reverse-transcriptase polymerase chain reaction (PCR) assay were included. Exclusion Criteria: Patients who had a past medical history of any chronic illness (related to respiratory, cardiology, immunology, neurology, metabolic, etc) were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient medical files | ABO blood type distribution will be different in COVID-19 | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, ABO blood group, infection risk
Epidemiology and Clinical Course of Pulmonary Embolism During and After Hospitalisation

Study Overview
=================
Brief Summary
-----------------
This survey will allow to identify PE prognostic, but also long-term complications, i.e. recurrence rate, on-treatment bleedings, deep-vein thrombosis sequella, pulmonary hypertension rate, and chronic pulmonary disease rate without PH. This database should help us identify risk-factors for each event.

Official Title
-----------------
Pulmonary Embolism Registry

Conditions
-----------------
Pulmonary Embolism

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pulmonary embolisms hospitalised in Nice hospital. acceptation to enter in the cohorte survey Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pulmonary Embolism without reccurence or complication<br>Pulmonary Embolism without reccurence or complication | Other: no intervention<br>* no intervention<br>|
| Pulmonary Embolism with reccurence or complication<br>Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension. | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reccurence | number of patient with Documented symptomatic pulmonary embolism reccurence | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary hypertension | number of patients with Confirmed pulmonary hypertension after pulmonary embolism | 10 years | 
| Chronic pulmonary disease without hypertension | number of patients with dyspnea but without pulmonary hypertension, Documented non-reperfused pulmonary areas | 10 years |
Molecular Epidemiology of Benzene-exposed Workers.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the health effects of benzene exposure in workers in Shanghai, China.

Detailed Description
-----------------
The purpose of this study is to investigate the dose-response relationship between benzene exposure and blood diseases in Shanghai workers and to characterize genetic polymorphisms that are associated with increased risk of developing benzene hematotoxicity.

Official Title
-----------------
Molecular Epidemiology of Benzene-exposed Workers in Shanghai,China

Conditions
-----------------
Hematologic Diseases

Intervention / Treatment
-----------------
* Other: Shanghai workers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Worked for at least one year in a monitored environment Have at least one physical examination recorded - Exclusion Criteria: History of cancer, radiation exposure, chemotherapy -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Shanghai Workers<br>Shanghai Workers | Other: Shanghai workers<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigate the dose-response relationship between benzene exposure and blood diseases in Shanghai workers. | Investigate the dose-response relationship between benzene exposure and blood diseases in Shanghai workers | August 2003 - December 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterize genetic polymorphisms that are associated with increased risk of developing benzene hematotoxicity. | Characterize genetic polymorphisms that are associated with increased risk of developing benzene hematotoxicity. | August 2003 - December 2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hematologic Diseases, Benzene, Genetic Polymorphisms
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

Study Overview
=================
Brief Summary
-----------------
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.

Official Title
-----------------
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed 2 years in the FUNCTION (WA19926) trial Patient has provided written informed consent and is willing to comply with the requirements of this study protocol Exclusion Criteria: Requirement for immediate treatment with a biologic therapy following completion of the FUNCTION (WA19926) trial as per treating physician judgement. Presence of any condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of RA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Biologic Treatment | To describe the rate of requiring biologic treatment over 2 years following completion of the FUNCTION study | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment after completion of FUNCTION study | To determine the type of RA treatment regimen used by the treating physician upon completion of the FUNCTION study | Baseline | 
| Rate of requiring treatment intensification | To determine the rate of requiring treatment intensification with a traditional DMARD(s) completion of the FUNCTION study. The durability of response after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study. | 2 years | 
| Change in functional status | The change in patient-reported functional status over 2 years after tocilizumab withdrawal or maintaining Mtx or changing DMARD(s) | 2 years | 
| Work productivity | To determine work productivity over 2 years after completion of the FUNCTION study | 2 years | 
| Healthcare Utilization | To determine health-care utilization over 2 years after completion of the FUNCTION study | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tocilizumab, Early Rheumatoid Arthritis, Observational, Canadian
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to investigate whether blood markers can be used to predict the development of bone metastases and to assess the efficacy and safety of zoledronic acid in cancer treatment induced bone loss.

Official Title
-----------------
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Conditions
-----------------
Cancer Prostate

Intervention / Treatment
-----------------
* Drug: Zoledronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All stages of prostate cancer without bone metastases No evidence of severe osteoporosis ECOG performance status 0, 1 or 2 Exclusion Criteria: Surgery / fracture at the lumbosacral spine, bilateral hip implants Evidence of metabolic bone diseases, Treatment with bisphosphonates or calcitonin within the previous year or chronic systemic corticosteroid treatment Abnormal kidney or liver function Other cancers within the last 5 years Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ZOL446 (zoledronic acid)<br> | Drug: Zoledronic acid<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| If and to what extent rising levels of the bone resorption marker CTX can be used as an indicator for the development of bone metastases, diagnosed via bone scintigraphy. |  | at 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| If and to what extent rising levels of PSA can be used as an indicator for the development of bone metastases |  | at 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Zoledronic acid, Zometa, prostate cancer, osteoporosis
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.

Official Title
-----------------
A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consenting patients who participated in the core clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety, atopic dermatitis, adverse event, SAE, extension
Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of two different loading doses of Clopidogrel and a reloading of Atorvastatin in the prevention of periprocedural ischemic brain damage in patients undergoing carotid angioplasty.

Official Title
-----------------
Efficacy of Two Different Pre-Intervention Therapeutic Strategies With Clopidogrel and Atorvastatin for the Prevention of Cerebral Damage During Carotid Artery Stenting. Armyda-Caro Randomized Trial.

Conditions
-----------------
Carotid Stenosis

Intervention / Treatment
-----------------
* Drug: Clopidogrel
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic and asymptomatic patients with finding of significant carotid stenosis Exclusion Criteria: patients with acute injuries to the baseline MRI of the brain, patients with active bleeding, contraindications to statin therapy and MRI contraindications (pacemaker/claustrophobic).

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Antiplatelet before carotid artery stenting<br>Clopidogrel 600 mg after carotid artery stenting | Drug: Clopidogrel<br>* Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting<br>|
| Active Comparator: Statin therapy before carotid artery stenting<br>Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload. | Drug: Atorvastatin<br>* Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral damage | Incidence of stroke at 30 days (defined as a neurologic deficit lasting> 24 hours with MRI evidence of cerebral ischemic injury) or transient ischemic attack (TIA); - Evidence of new onset acute ischemic lesions on MRI-DWI brain after the procedure, even in the absence of specific neurological symptoms | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding complications | Effect on the 30-day major and minor bleeding (according to the TIMI definition); - Incidence of post-procedural vascular complications (pseudoaneurysm, AV fistula, hematoma> 5 cm). | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Therapeutic strategies for carotid artery stenting
Effects of Percutaneous Coronary Intervention in Patients With Cardiac Arrest After Acute Myocardial Infarction: a 2-Year Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is To assess percutaneous coronary intervention 's effect on short- and long- term outcomes, and complication incidence in resuscitated victims of cardiac arrest after acute myocardial infarction

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Device: percutaneous coronary intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: underwent successful cardiopulmonary resuscitation from CA after AMI Exclusion Criteria: late tumor; underwent Coronary Artery Bypass Grafting after CAG; with no attempted resuscitation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The PCI group<br>The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA. | Device: percutaneous coronary intervention<br> <br> |
| Non-PCI group<br>Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac arrest, percutaneous coronary intervention, cardiogenic shock, outcome
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.

Official Title
-----------------
Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma

Conditions
-----------------
Asthma, House Dust Mite Allergy

Intervention / Treatment
-----------------
* Biological: SLIT tablets of house dust mite allergen extracts
* Biological: Matching placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent. Male or female patient from 18 to 50 years. Diagnosed asthma with medical history consistent with HDM-induced allergic asthma. Positive SPT to House Dust Mites(HDM)and HDM-specific IgE serum value ≥ 0.7 kU/L. Stable asthma treatments. Spirometry with best FEV1 > 70% of the predicted value. Spirometry with reversibility of FEV1 of ≥ 12% and ≥ 200 mL. Asthma Control Test™ (ACT) score ≥ 20. Exclusion Criteria: Current smoker or former smoker with > 10 pack/year history. Co-sensitisation to any allergen possibly leading to clinically relevant respiratory allergy likely to significantly change the symptoms of the patient throughout the treatment period. Patient with a past or current disease, which as judged by the Investigator, may affect the patient's participation in or the outcome of this study. Patient with any oral condition that could confound the safety assessments or planning to have a dental extraction during the study. Female patient pregnant or breast-feeding/lactating. Female patient of childbearing potential not using a medically accepted contraceptive method. Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs). Patient who received allergen immunotherapy for HDM in the last 10 years. Ongoing treatment by immunotherapy with another allergen.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SLIT tablets of HDM allergen extracts<br> | Biological: SLIT tablets of house dust mite allergen extracts<br>* 10 dosing days<br>|
| Placebo Comparator: Placebo<br> | Biological: Matching placebo<br>* 10 dosing days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety, tolerability as indicated by adverse events and safety laboratory evaluation |  | 10 dosing days |
Data Collection of OCT and OCTA-based Ocular Measurements

Study Overview
=================
Brief Summary
-----------------
Data Collection of OCT and OCTA-based Ocular Measurements

Detailed Description
-----------------
The purpose of this study is to collect measurements of anatomical structures of the posterior pole of the eye based on OCT scans in subjects without clinical signs of pathology.

Official Title
-----------------
Data Collection of OCT and OCTA-based Ocular Measurements

Conditions
-----------------
Eyes Without Ocular Pathology

Intervention / Treatment
-----------------
* Device: SD-OCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No glaucoma No retinal pathology No systemic disorders impacting the eye No ocular surgery or medical treatment of ocular condition Exclusion Criteria: High IOP Poor vision Clinical findings consistent with pathology Unable to complete the study

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal thickness | micrometers | Day 1 |